Display options
Share it on

World J Diabetes. 2015 Jun 10;6(5):744-51. doi: 10.4239/wjd.v6.i5.744.

Emerging links between type 2 diabetes and Alzheimer's disease.

World journal of diabetes

Gumpeny R Sridhar, Gumpeny Lakshmi, Gumpeny Nagamani

Affiliations

  1. Gumpeny R Sridhar, Gumpeny Lakshmi, Gumpeny Nagamani, Endocrine and Diabetes Centre, Department of Obstetrics and Gynecology, Andhra Medical College, Visakhapatnam 530002, India.

PMID: 26069723 PMCID: PMC4458503 DOI: 10.4239/wjd.v6.i5.744

Abstract

Type 2 diabetes mellitus and Alzheimer's disease are both associated with increasing age, and each increases the risk of development of the other. Epidemiological, clinical, biochemical and imaging studies have shown that elevated glucose levels and diabetes are associated with cognitive dysfunction, the most prevalent cause of which is Alzheimer's disease. Cross sectional studies have clearly shown such an association, whereas longitudinal studies are equivocal, reflecting the many complex ways in which the two interact. Despite the dichotomy, common risk and etiological factors (obesity, dyslipidemia, insulin resistance, and sedentary habits) are recognized; correction of these by lifestyle changes and pharmacological agents can be expected to prevent or retard the progression of both diseases. Common pathogenic factors in both conditions span a broad sweep including chronic hyperglycemia per se, hyperinsulinemia, insulin resistance, acute hypoglycemic episodes, especially in the elderly, microvascular disease, fibrillar deposits (in brain in Alzheimer's disease and in pancreas in type 2 diabetes), altered insulin processing, inflammation, obesity, dyslipidemia, altered levels of insulin like growth factor and occurrence of variant forms of the protein butyrylcholinesterase. Of interest not only do lifestyle measures have a protective effect against the development of cognitive impairment due to Alzheimer's disease, but so do some of the pharmacological agents used in the treatment of diabetes such as insulin (especially when delivered intranasally), metformin, peroxisome proliferator-activated receptors γ agonists, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes must be recognized as a risk for development of Alzheimer's disease; clinicians must ensure preventive care be given to control and postpone both conditions, and to identify cognitive impairment early to manage it appropriately.

Keywords: Butyrylcholinesterase; Cognition; Dementia; Insulin; Insulin resistance

References

  1. Diabetologia. 2011 Dec;54(12):3022-7 - PubMed
  2. Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):131-45 - PubMed
  3. J Cell Mol Med. 2011 Aug;15(8):1747-56 - PubMed
  4. JAMA Neurol. 2013 Sep 1;70(9):1167-72 - PubMed
  5. Med Hypotheses. 2010 Dec;75(6):648-51 - PubMed
  6. Eur J Pharmacol. 2004 Apr 19;490(1-3):5-12 - PubMed
  7. Lipids Health Dis. 2006 Nov 11;5:28 - PubMed
  8. Diabetes. 1999 Oct;48(10):1915-21 - PubMed
  9. Clin Chim Acta. 2007 Mar;378(1-2):128-35 - PubMed
  10. Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8628-33 - PubMed
  11. Br J Clin Pharmacol. 2011 Mar;71(3):365-76 - PubMed
  12. N Engl J Med. 2013 Aug 8;369(6):540-8 - PubMed
  13. Diabetes Care. 2014 Nov;37(11):3076-83 - PubMed
  14. Neuron. 1996 Apr;16(4):881-91 - PubMed
  15. Neurology. 1995 Jun;45(6):1161-8 - PubMed
  16. Lancet. 2012 Jun 16;379(9833):2291-9 - PubMed
  17. Amyloid. 2007 Jun;14(2):119-31 - PubMed
  18. Diabetes. 1999 Mar;48(3):557-63 - PubMed
  19. Brain Res Dev Brain Res. 1991 Oct 21;62(2):293-6 - PubMed
  20. Age Ageing. 2008 Jul;37(4):458-61 - PubMed
  21. Curr Alzheimer Res. 2008 Oct;5(5):438-47 - PubMed
  22. Diabetes Care. 2013 Oct;36(10):2981-7 - PubMed
  23. Hum Mol Genet. 1997 Oct;6(11):1933-6 - PubMed
  24. Science. 2014 May 16;344(6185):687-9 - PubMed
  25. Neurology. 2010 Aug 31;75(9):764-70 - PubMed
  26. J Clin Invest. 2012 Apr;122(4):1191 - PubMed
  27. Indian J Endocrinol Metab. 2012 Dec;16(Suppl 3):S601-10 - PubMed
  28. Diabetes Care. 2004 May;27(5):1047-53 - PubMed
  29. Diabetes. 2010 Nov;59(11):2883-9 - PubMed
  30. J Diabetes Investig. 2012 Oct 18;3(5):413-23 - PubMed
  31. Diabetes. 2014 Dec;63(12):3992-7 - PubMed
  32. JAMA. 2009 Apr 15;301(15):1565-72 - PubMed
  33. Diabetes. 2014 Feb;63(2):663-74 - PubMed
  34. Lipids Health Dis. 2005 Sep 08;4:18 - PubMed
  35. N Engl J Med. 2007 May 3;356(18):1842-52 - PubMed
  36. Neurosci Lett. 1990 Jul 31;115(2-3):279-85 - PubMed
  37. J Assoc Physicians India. 2010 May;58:290-4 - PubMed
  38. J Clin Endocrinol Metab. 2012 Feb;97(2):366-76 - PubMed
  39. Diabetes Care. 2010 Oct;33(10 ):2169-74 - PubMed
  40. Med Hypotheses. 2007;69(6):1272-6 - PubMed
  41. Front Endocrinol (Lausanne). 2014 Jul 08;5:110 - PubMed
  42. J Alzheimers Dis. 2014;42 Suppl 4:S515-23 - PubMed
  43. Science. 2009 Nov 13;326(5955):1005-7 - PubMed
  44. Am J Epidemiol. 1997 Feb 15;145(4):301-8 - PubMed
  45. Diabetes Care. 2009 Feb;32(2):221-6 - PubMed
  46. Diabetologia. 2004 Aug;47(8):1437-41 - PubMed
  47. J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):917-22 - PubMed
  48. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12 - PubMed
  49. PLoS One. 2014 Jul 02;9(7):e100778 - PubMed
  50. Dement Geriatr Cogn Disord. 2010;30(5):381-6 - PubMed
  51. Neurology. 1999 Dec 10;53(9):1937-42 - PubMed
  52. Neurology. 2011 Sep 20;77(12):1126-34 - PubMed
  53. Bratisl Lek Listy. 2013;114(12):726-34 - PubMed
  54. Physiol Behav. 1991 Feb;49(2):335-8 - PubMed

Publication Types